Treatment.com AI Inc. and its wholly owned subsidiary Rocket Doctor welcomed recent remarks by U.S. Secretary of Health and Human Services Robert F. K

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatmen.com AI.
2. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) and its wholly owned subsidiary Rocket Doctor welcomed recent remarks by U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., who voiced strong support for expanding telehealth and artificial intelligence (AI) tools in the American healthcare system. Speaking during a House Appropriations Committee Budget Hearing on May 14, Secretary Kennedy advocated for AI-driven diagnostics to reduce emergency room visits and enhance home-based care options.

“We are going to dramatically revolutionize the availability of telehealth and AI so that people can avoid emergency rooms by getting treated at home,” said Kennedy. He specifically cited technologies capable of diagnosing conditions such as strep throat using smartphone cameras.

The comments align closely with the operating model of Rocket Doctor, which provides a virtual platform for physicians to launch and manage remote practices in New York and California. Serving Medicare and Medicaid patients in both urban and rural communities, Rocket Doctor employs AI-powered diagnostic tools and Bluetooth-enabled medical devices to assist in clinical decisions, reducing the need for hospital-based interventions. According to the company, its services have helped over 4,000 patients avoid emergency care visits, with additional support from regional hospitals such as Georgian Bay General Hospital in Ontario.

“Secretary Kennedy’s remarks validate what we’ve been building,” said Dr. William Cherniak, CEO and Founder of Rocket Doctor, in the news release. “Our system is designed to address the problem of patients using more costly emergency services when care could be delivered safely at home.”

Rocket Doctor was recently named Clinical Innovator of the Year by the American Telemedicine Association. Its parent company, Treatment.com AI, complements this effort with its proprietary Global Library of Medicine (GLM), a physician-developed AI platform that assists in patient onboarding, triage, and diagnostic support.

“AI is offering the possibility to significantly impact healthcare for the 3 Ps: the Patient, the Provider, and the Payer,” said Dr. Essam Hamza, CEO of Treatment.com AI. “What Secretary Kennedy described isn’t hypothetical. It’s happening now.”

AI-Powered Healthcare: Scaling Amid Opportunity and Complexity

A report from Exploring Topics published on April 29 highlighted that 71% of U.S. healthcare industry leaders expected improved profitability in 2025, driven largely by AI-enabled automation and data efficiency. Among healthcare organizations that had implemented generative AI tools, 54% had already observed a meaningful return on investment. The report stated, “Healthcare AI searches are up 911% in the last five years,” reflecting growing institutional interest in AI integration. However, 72% of healthcare organizations also expressed concern about security risks associated with the rapid advancement of AI technologies, including vulnerabilities in connected smart devices.

Artificial intelligence (AI) adoption in healthcare continued to expand across clinical, administrative, and research domains as providers sought to streamline care delivery and reduce costs. According to Techtarget on May 1, hospitals and provider organizations had integrated AI into workflows to enable more personalized treatment plans and improve communication across stakeholders. The article noted that AI-powered clinical decision support systems (CDSS) were evolving from standalone tools into deeply integrated solutions capable of analyzing both structured and unstructured data within electronic health records.

AI in Healthcare reported on May 16 that while healthtech unicorns remained rare, making up only 8% of the more than 1,000 unicorns globally, they were becoming more prominent as structural barriers began to ease. Venture capital firm SignalFire observed that healthcare startups were previously hindered by complex regulations and fragmented buyer environments but now benefitted from favorable timing and growing talent pools. “Healthcare is leapfrogging,” the report stated, adding that healthtech founders were increasingly combining clinical insight with operational expertise from outside the healthcare sector.

Looking Ahead: Where Treatment.com AI Is Gaining Ground

Treatment.com AI's investor presentation details how the company is positioning itself at the intersection of healthcare delivery, artificial intelligence, and virtual care enablement through the integration of its GLM platform and expanding acquisition strategy. The company’s AI engine, which includes over 10,000 peer-reviewed clinical entries, supports differential diagnoses, recommends lab tests, and suggests treatment pathways—all tailored geographically and reviewed by credentialed medical experts.

Rocket Doctor, acquired in 2024, has grown its SaaS-based annual recurring revenue to approximately CA$1.9 million, reflecting 88% year-over-year growth. While reported in Canadian dollars, these financial figures were unaudited and included a reduction in net loss from approximately CA$2.4 million in 2023 to CA$1.3 million in 2024. The platform has been used in more than 12,500 total appointments, with an average monthly growth rate of 20%, according to the company’s investor presentation from March 2025.

Additional momentum comes from Treatment.com AI’s acquisition of Alea Health, which expands voice AI and mental health capabilities and opens channels into the Middle East healthcare market. The company's proprietary voice agent, CARA, is currently deployed for multilingual patient triage, post-discharge monitoring, and remote therapy.

Partnerships with institutions such as the Mayo Clinic and the University of Minnesota Medical School also support the company’s strategy of integrating AI into clinical education and provider workflows. With AI solutions already showing a 92% accuracy rate in simulated diagnostic assessments, Treatment.com AI is advancing its presence among medical schools and enterprise healthcare partners, including discussions with over 30 academic institutions and 10 enterprise providers.

As of February 2025, Treatment.com AI reported 57,851,494 basic shares outstanding and a market capitalization of approximately US$25.45 million based on its March 14, 2025, closing price. The company trades on the Canadian Securities Exchange under the symbol TRUE, the OTC under TREIF, and the Frankfurt exchange as 939.

Ownership and Share Structure

According to Refinitiv, insiders own approximately 5.1% of Treatment.com AI. Institutions hold .81%. Retail investors own the remaining 94.1%.   

The company has 75.5 million outstanding common shares and has 71.65 million free float traded shares.  The market cap is approximately CA$25.43  million.

Over the past 52 weeks, the company traded between CA$0.0471 to $0.9116 per share